What are the recommended guidelines for osteoporosis prophylaxis and appropriate use of proton‑pump inhibitors in adults receiving systemic glucocorticoid therapy?

Osteoporosis Prophylaxis and PPI Use in Systemic Glucocorticoid Therapy

All adults receiving ≥2.5 mg/day prednisone (or equivalent) for >3 months require osteoporosis screening within 6 months, and those at medium, high, or very high fracture risk should receive oral bisphosphonates as first-line therapy; PPIs should be avoided or minimized in these patients due to increased fracture risk with long-term use (≥5-7 years). 1, 2

Who Requires Osteoporosis Assessment

Screen all patients likely to receive oral glucocorticoids for ≥3 months:

• Women and men ≥50 years of age 2
• Adults receiving ≥2.5 mg/day prednisone equivalent for >3 months 1
• Patients with history of fragility fracture, low body weight, or comorbidities associated with osteoporosis 1, 2
• Premenopausal women and men <50 years with Z-score ≤-2 or fragility fracture history (refer to bone specialist) 2

How to Assess Fracture Risk

Perform comprehensive risk stratification using:

• DXA BMD testing of lumbar spine, total hip, femoral neck, and one-third radius when indicated 1
• Vertebral fracture assessment (VFA) by DXA or conventional radiography for patients with T-score <-1.0, height loss >4 cm, or chronic glucocorticoid use 1
• FRAX tool (age ≥40 years) with glucocorticoid dose-adjustment factor for prednisone >7.5 mg/day 1, 2
• Systematic vertebral imaging to detect prevalent fractures 2
• Fall risk assessment 2

Risk stratification categories:

• Medium risk: No recent fracture history (within 2 years) 2
• High risk: Recent fracture history and/or ≥1 vertebral fracture (Genant grade ≥2) 2
• Very high risk: Age ≥70 years with recent hip/pelvis fracture and/or ≥1 vertebral fracture (Genant grade ≥2) 2

Who Requires Pharmacologic Treatment

Initiate anti-osteoporosis therapy in women and men ≥50 years with any of the following:

• Recent vertebral or non-vertebral fracture (within 2 years) 2
• Glucocorticoid dosage ≥7.5 mg/day 2
• Age ≥70 years 2
• T-score ≤-1.5 2
• 10-year probability risk above country-specific glucocorticoid dose-adjusted FRAX thresholds 2
• FRAX 10-year major osteoporotic fracture probability ≥20% or hip fracture probability ≥3% 1

First-Line Pharmacologic Treatment by Risk Category

Medium Fracture Risk

Oral bisphosphonates are strongly recommended:

• Alendronate 70 mg weekly (preferred) 1, 2
• Risedronate 35 mg weekly (alternative) 1, 2

High Fracture Risk

Zoledronic acid or denosumab are conditionally recommended:

• Zoledronic acid 5 mg IV annually 2
• Denosumab 60 mg SC every 6 months 2
• Critical caveat: Denosumab requires mandatory transition to bisphosphonate upon discontinuation to prevent rebound vertebral fractures 1

Very High Fracture Risk

Teriparatide is conditionally recommended as first-line:

• Teriparatide administered daily subcutaneously 2
• Critical caveat: Sequential bisphosphonate therapy is required after discontinuation to prevent bone loss 1, 2

Universal Non-Pharmacologic Measures

All patients on glucocorticoids ≥3 months require:

• Calcium intake 1,000-1,200 mg/day (dietary plus supplements if needed) 1, 2
• Vitamin D supplementation 800-1,000 IU/day to achieve 25(OH)D concentration of 50-125 nmol/L 1, 2
• Regular weight-bearing exercise combining balance training, progressive resistance strengthening, flexibility, and endurance 1
• Smoking cessation and alcohol limitation to ≤1-2 drinks/day 1
• Fall risk minimization 2

PPI Use and Osteoporosis Risk

PPIs should be avoided or minimized in glucocorticoid-treated patients due to compounding fracture risk:

Evidence of PPI-Associated Fracture Risk

• PPI use ≥7 years significantly increases osteoporosis-related fracture risk (adjusted OR 1.92,95% CI 1.16-3.18) 3
• Hip fracture risk increases after ≥5 years exposure (adjusted OR 1.62,95% CI 1.02-2.58), with highest risk after ≥7 years (adjusted OR 4.55,95% CI 1.68-12.29) 3
• Long-term PPI use (>180 days) increases osteoporosis risk (HR 1.57,95% CI 1.28-1.92) and hip fracture risk (pooled HR 1.82,95% CI 1.04-3.19) 4
• PPIs reduce TRPM7 channel expression in bone cells and cause calcium/magnesium ionic imbalance, directly impairing bone remodeling 5

Clinical Approach to PPIs in Glucocorticoid Users

When PPI use is considered necessary:

• Verify appropriate indication (history of complicated GI event, concurrent aspirin use, age ≥65 years) 6
• Use lowest effective dose for shortest duration 7
• Consider H2-receptor antagonists as alternative when appropriate 7
• Monitor calcium and magnesium levels 5
• Ensure adequate calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day) supplementation 1
• Perform BMD monitoring more frequently (every 2 years minimum) 1

Avoid PPIs when:

• No high-risk GI indication exists 6
• Patient already has T-score ≤-1.5 or established osteoporosis 1, 2
• Multiple osteoporosis risk factors are present 7

Treatment Monitoring

Follow-up DXA BMD testing:

• Perform 1-5 years after initiating or changing therapy, tailored to clinical circumstances 1
• Use same center and scanner for consistency 1
• Calculate least significant change (LSC) based on facility precision error 1

Monitor clinical risk factors at each visit:

• New fragility fractures 2
• Height loss (vertebral imaging if >4 cm) 1
• Fall risk changes 2
• Glucocorticoid dose adjustments 2

Critical Pitfalls to Avoid

• Failure to initiate osteoporosis therapy concomitantly with glucocorticoids in elderly patients leads to preventable fractures 8
• Discontinuing denosumab or teriparatide without transitioning to bisphosphonate causes severe rebound vertebral fractures 1, 2
• FRAX underestimates fracture risk in patients on very high glucocorticoid doses (≥30 mg/day prednisone) 1
• Prescribing long-term PPIs without appropriate GI indication compounds osteoporosis risk in glucocorticoid users 3, 7, 4
• Relying solely on BMD without incorporating clinical risk factors (age, fracture history, glucocorticoid dose) misses high-risk patients 1, 2